← Back to All Filings

BIO-TECHNE CEO Disposes of $144k in Stock for Tax Purposes

Low SignificanceNovember 5, 2025 at 5:02:50 PM EST

BIO-TECHNE Corp

$TECH4CIK: 0000842023

Subscribe to track TECH

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

BIO-TECHNE CEO Disposes of $144k in Stock for Tax Purposes

Company: BIO-TECHNE Corp (TECH) Form: 4 | Filed: 2025-11-05 Significance: Low

Insider: Kelderman Kim Title: Chief Executive Officer | Relationship: Director, Officer

Transaction: • Type: Tax Withholding • Shares: 2,303 • Price: $62.57 • Value: $144,099 • Owned After: 48,665

Key Insight: The CEO disposed of shares to cover tax liabilities (Transaction Code 'F'), a common and non-discretionary event with low market significance.

Market Context: This transaction represents a negligible fraction (<0.002%) of the company's $9.74 billion market capitalization and has no bearing on insider sentiment.

View Full Filing

This is PUBLIC SEC data for educational purposes. Not investment advice.

Comprehensive Analysis

SEC Filing Analysis: BIO-TECHNE Corp (TECH)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: The CEO of BIO-TECHNE Corp executed a routine, non-discretionary disposition of shares to cover tax obligations, a transaction with minimal market impact.
  • Market Impact: Neutral. This type of transaction is common and does not reflect a change in the insider's investment thesis.

Company Information

FieldValue
CompanyBIO-TECHNE Corp
Ticker SymbolTECH
CIK0000842023
IndustryBIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

FieldValue
NameKelderman Kim
CIK0001739054
Title/PositionChief Executive Officer
RelationshipDirector, Officer

Transaction Details

FieldValue
Form Type4
Transaction Date2025-11-03
Transaction CodeF - Payment of tax liability by withholding securities
Security TypeCommon Stock
Shares Involved2,303
Price Per Share$62.57
Total Value$144,098.71
Shares Owned After48,665
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$144,098.71
% of Market Cap0.0015%
Shares Transacted2,303
% of Shares Outstanding0.0015%
Post-Transaction Ownership48,665 shares (0.031% of outstanding)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: The $144k transaction is immaterial against BIO-TECHNE's $9.74 billion market capitalization.
  • Ownership Concentration: The CEO's direct holdings remain minimal at 0.031% of total shares outstanding.
  • Transaction Significance: The transaction's value is less than 0.01% of both market cap and shares outstanding, placing it firmly in the 'Low' significance category. It is a procedural financial management action, not a strategic trade.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: Transaction code 'F' signifies a non-discretionary disposition to cover taxes, often related to the vesting of equity awards. It is not an open-market sale and carries no sentiment signal.

Volume & Sentiment

  • Expected Volume Impact: Negligible. The transaction is a withholding of shares and not an open market trade, so it will not directly impact trading volume.
  • Sentiment Indicator: Neutral. This is a routine administrative action required for compensation and tax purposes.

Additional Context

Transaction Notes

  • The transaction is coded 'F', which the SEC defines as "Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3." This confirms the non-discretionary nature of the disposal.
Topics:#SECFiling#InsiderTrading#TECH#BioTechne#Form4#CEOMoves#StockMarket#Investing#FinancialAnalysis

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.